Heminevrin (Clomethiazole Edisilate)

Heminevrin is indicated for medical management of conditions that require central nervous system depression.

• Treatment of alcohol withdrawal syndrome under medical supervision.
• Short‑term sedation for patients requiring procedural or intensive care sedation.
• Adjunctive therapy in the management of acute agitation when other agents are unsuitable.
• Use in controlled settings for severe insomnia when alternative treatments have failed.
• Management of severe anxiety associated with acute withdrawal states, as part of a comprehensive treatment plan.

The safety profile of Heminevrin includes a range of observed effects that vary in frequency and severity.

Common

• Persistent drowsiness or somnolence that may affect daily activities.
• Episodes of dizziness or a light‑headed sensation, particularly when standing quickly.
• Mild to moderate headache that can be intermittent.
• Nausea, occasional vomiting, or mild gastrointestinal upset.
• Transient visual disturbances such as blurred vision.

Serious

• Respiratory depression that can be life‑threatening, especially when taken with alcohol or other CNS depressants.
• Marked hypotension or cardiovascular instability requiring medical monitoring.
• Significant elevation of liver enzymes or signs of hepatic injury.

When prescribing Heminevrin, clinicians should consider several precautionary measures to minimize risk and ensure safe use.

• Assess patient history for respiratory disorders, liver disease, or cardiovascular conditions before initiating therapy.
• Avoid use in individuals with known hypersensitivity to clomethiazole or related compounds.
• Limit duration of treatment to the shortest effective period to reduce dependence potential.
• Monitor vital signs, especially respiratory rate and blood pressure, during therapy.
• Use caution in elderly patients due to increased sensitivity to sedative effects.
• Evaluate concomitant use of alcohol or other CNS depressants and advise abstinence.

Heminevrin can interact with other substances that affect the central nervous system or hepatic metabolism, requiring careful management.

Avoid

• Alcohol and other sedative‑hypnotic agents, which may cause additive respiratory depression.
• Opioids or strong analgesics, due to increased risk of profound CNS depression.
• Benzodiazepines, as combined use can lead to excessive sedation and impaired psychomotor function.

Use with caution

• Antidepressants that influence serotonin levels, such as SSRIs, because of potential serotonergic effects.
• Anticonvulsants metabolized by hepatic enzymes (e.g., carbamazepine, phenytoin) that may alter clomethiazole clearance.
• Herbal supplements like St John’s wort that induce CYP enzymes and could reduce drug exposure.